Compare JD.Com Inc (JD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Novo Nordisk A/S — how do they compare? JD.Com Inc trades at $27.09 (market cap $36.62B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 4.5× JD.Com Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Novo Nordisk A/S for 116 Days on average.
| JD | NVO | |
|---|---|---|
Market Cap | $36.62B | $165.31B |
Volume | 6,571,477 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $63.98 |
52-Week Low | $25.19 | $35.29 |
Typical Hold Time | 85 Days | 116 Days |
Enterprise Value | $19.26B | $179.56B |
Dividend Yield | 3.72% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.91, down 0.44% on the day, with a bullish technical signal despite mixed moving average indicators. The company shows strong fundamentals with revenue growth to $1.31 trillion in 2025 and consistent earnings beats, though net margins compressed to 1.13%. Recent news highlights JD's potential EU approval for its $2.5 billion Ceconomy acquisition and positive analyst sentiment with 69.6% buy ratings.
JD presents a compelling value opportunity with attractive valuation multiples (P/E 17.9, P/S 0.2) and strong cash position ($234B), though investors face risks from regulatory scrutiny and competitive pressures in China's e-commerce sector. The consensus price target of $35.86 suggests 33% upside potential from current levels.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
